Clinical trial
A Study of LY573636-Sodium in the Treatment of Patients With Metastatic Soft…
NCT00490451 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00490451 |
|---|---|
| Title | A Study of LY573636-Sodium in the Treatment of Patients With Metastatic Soft Tissue Sarcoma |
| Official title | A Phase 2 Study of LY573636-Sodium Administered as Second-line or Third-line Treatment in Patients With Unresectable or Metastatic Soft Tissue Sarcoma |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Sarcoma, Soft Tissue |
| Intervention type | Drug |
| Interventions | LY573636-sodium |
| Enrollment | 101 |
| Start date | Aug 1, 2007 |
| Primary completion | Feb 1, 2010 |
| Completion | Feb 1, 2010 |
| First posted | Jun 22, 2007 |
| Last update posted | Sep 18, 2019 |
| Countries | Argentina, Spain, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: